Skip to Content
Merck
  • Dynamic changes in lymphocyte GRK2 levels in cardiac transplant patients: a biomarker for left ventricular function.

Dynamic changes in lymphocyte GRK2 levels in cardiac transplant patients: a biomarker for left ventricular function.

Clinical and translational science (2010-05-07)
Raphael E Bonita, Philip W Raake, Nicholas J Otis, J Kurt Chuprun, Talya Spivack, Abhijit Dasgupta, David J Whellan, Paul J Mather, Walter J Koch
ABSTRACT

G protein-coupled receptor kinase 2 (GRK2), which is upregulated in the failing human myocardium, appears to have a role in heart failure (HF) pathogenesis. In peripheral lymphocytes, GRK2 expression has been shown to reflect myocardial levels. This study represents an attempt to define the role for GRK2 as a potential biomarker of left ventricular function in HF patients. We obtained blood from 24 HF patients before and after heart transplantation and followed them for up to 1 year, also recording hemodynamic data and histological results from endomyocardial biopsies. We determined blood GRK2 protein by Western blotting and enzyme-linked immunosorbent assay. GRK2 levels were obtained before transplant and at first posttransplant biopsy. GRK2 levels significantly declined after transplant and remained low over the course of the study period. After transplantation, we found that blood GRK2 significantly dropped and remained low consistent with improved cardiac function in the transplanted heart. Blood GRK2 has potential as a biomarker for myocardial function in end-stage HF.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-GRK 2/3 (βARK 1/2) Antibody, clone C5/1.1, clone C5/1.1, Upstate®, from mouse